Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Therapeutics

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2011.06.016PMID 21802144
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction.

  2013cited by this paper
• Saxagliptin

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes

  2012cited by this paper
• Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

  2011cited by this paper
• Saxagliptin, a potent, selective inhibitor of DPP‐4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

  2011cited by this paper
• Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

  2011cited by this paper
• Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

  2011cited by this paper
• Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

  2011cited by this paper
• Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

  2011cited by this paper
• Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

  2010cited by this paper
• Effect of a High‐Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects

  2010cited by this paper
• Choosing among the incretin agents and why it matters.

  2010cited by this paper
• Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2010cited by this paper
• Dipeptidylpeptidase-4 Inhibitors (Gliptins)

  2010cited by this paper
• Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

  2010cited by this paper
• Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

  2010cited by this paper
• Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

  2010cited by this paper
• DPP-4 inhibitors: what may be the clinical differentiators?

  2010cited by this paper
• A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

  2010cited by this paper
• Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial

  2010cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  2009cited by this paper
• Changing the Treatment Paradigm for Type 2 Diabetes

  2009cited by this paper
• Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

  2009cited by this paper
• Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

  2009cited by this paper
• Alogliptin: a new addition to the class of DPP-4 inhibitors

  2009cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

  2009cited by this paper
• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

  2009cited by this paper
• DPP-4 Inhibitors in Clinical Practice

  2009cited by this paper
• Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

  2009cited by this paper
• Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

  2009cited by this paper
• Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with type 2 diabetes

  2009cited by this paper
• Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

  2009cited by this paper
• Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

  2009cited by this paper
• Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.

  2008cited by this paper
• Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes *

  2008cited by this paper
• Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

  2008cited by this paper
• Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.

  2008cited by this paper
• Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

  2008cited by this paper
• Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

  2008cited by this paper
• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Islet beta cell failure in type 2 diabetes.

  2006cited by this paper
• Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey.

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?

  2006cited by this paper
• Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

  2005cited by this paper
• Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

  2005cited by this paper
• Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

  2005cited by this paper
• Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

  2004cited by this paper
• Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

  2003cited by this paper
• Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1.

  2002cited by this paper

• Development and Validation of UHPLC-MS/MS Method for the Determination of SAX and 5-OH-SAX in Human Plasma and Its Application to a Pharmacokinetic Study.

  2026cites this paper
• Adamantane-linked 1,2,4-triazoles: Crystal structures, in vitro antimicrobial and anti-proliferative activities, and molecular docking analysis

  2025cites this paper
• Sitagliptin Alleviates Obesity in Immature Mice by Inhibiting Oxidative Stress and Inflammation

  2024cites this paper
• Shellac and locust bean gum coacervated curcumin, epigallocatechin gallate nanoparticle ameliorates diabetic nephropathy in a streptozotocin-induced mouse model.

  2024cites this paper
• Activation of AMPK/SIRT1/FOXO3a signaling by BMS-477118 (saxagliptin) mitigates chronic colitis in rats: uncovering new anti-inflammatory and antifibrotic roles

  2024cites this paper
• Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials’ meta-analysis studies

  2024cites this paper
• Understanding the Pharmacological and Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics

  2023cites this paper
• Co-delivery of saxagliptin and dapagliflozin by electrosprayed trilayer poly (D, L-lactide-co-glycolide) nanoparticles for controlled drug delivery.

  2022cites this paper
• Exploring the recent molecular targets for diabetes and associated complications

  2021cites this paper
• Simultaneous Determination of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin in Bulk Drug and Formulation by UPLC Q-TOF-MS

  2020cites this paper
• Sitagliptin's effects on bone tissue and osseointegration in diabetic rats.

  2019cites this paper
• Electrochemical determination of Saxagliptin hydrochloride with MWCNTs/CuO/4′aminobenzo-18-crown-6-ether composite modified carbon paste electrode

  2019cites this paper
• Anti-Diabetic and Anti-Nephritic Activities of Grifola frondosa Mycelium Polysaccharides in Diet-Streptozotocin-Induced Diabetic Rats Via Modulation on Oxidative Stress

  2018cites this paper
• Biocatalyzed synthesis of antidiabetic drugs: A review

  2018cites this paper
• Investigation of medicinal plants from Madagascar against DPP-IV linked to type 2 diabetes

  2018cites this paper
• DEVELOPMENT AND VALIDATION RP-HPLC METHOD FOR SAXAGLIPTIN MONOHYDRATE IN BULK AND PHARMACEUTICAL DOSAGE FORM

  2017cites this paper
• The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials

  2017cites this paper
• PROOF COVER SHEET

  2017cites this paper
• The Hypoglycemic, Hypolipidemic, and Anti-Diabetic Nephritic Activities of Zeaxanthin in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats

  2017cites this paper
• Investigation of hypoglycemic, hypolipidemic and anti‑nephritic activities of Paecilomyces tenuipesN45 in diet/streptozotocin‑induced diabetic rats.

  2017cites this paper
• Lycium barbarum Polysaccharide Mediated the Antidiabetic and Antinephritic Effects in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats via Regulation of NF-κB

  2016cites this paper
• Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China

  2016cites this paper
• Antidiabetic and Antinephritic Activities of Aqueous Extract of Cordyceps militaris Fruit Body in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats

  2016cites this paper
• Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea

  2016cites this paper
• Anti-diabetic activities of Paecilomyces tenuipes N45 extract in alloxan-induced diabetic mice.

  2016cites this paper
• Adamantane - A Lead Structure for Drugs in Clinical Practice.

  2016cites this paper
• Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

  2015cites this paper
• Saxagliptin: a novel antiparkinsonian approach.

  2015cites this paper
• Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.

  2015cites this paper
• Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on β‐cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对β细胞功能的影响：一项meta分析

  2015cites this paper
• Diabetes mellitus – an overview

  2015cites this paper
• Dipeptidil dipeptidase-IV inhibidors: from the theory to the practice

  2015cites this paper
• METHOD DEVELOPMENT AND VALIDATION OF SIMULTANEOUS DETERMINATION OF METFORMIN AND SAXAGLIPTIN IN PHARMACEUTICAL DOSAGE FORM BY RP-HPLC

  2015cites this paper
• Inhibidores de dipeptidil dipeptidasa-IV: de la teoría a la práctica

  2015cites this paper
• Regulation of glucose homeostasis by GLP-1.

  2014cites this paper
• DEVOLPMENT AND VALIDATION OF SIMPLE STABILITY INDICATING RP-HPLC METHOD FOR ANALYSIS OF SAXAGLIPTIN AND ITS FORCED DEGRADATION IMPURITIES IN BULK DRUG AND PHARMACEUTICAL DOSAGE FORM

  2014cites this paper
• The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors

  2014cites this paper
• Studies on the Antidiabetic Activities of Cordyceps militaris Extract in Diet-Streptozotocin-Induced Diabetic Sprague-Dawley Rats

  2014cites this paper
• Development and validation of simple stability indicating RP-HPLC method for analysis of saxagliptin and its forced degradation impurities in bulk drug and pharmaceutical dosage form.

  2014cites this paper
• Chapter 42 - Insulin, other hypoglycemic drugs, and glucagon

  2014cites this paper
• Spectrophotometric and spectrofluorimetric methods for the determination of saxagliptin and vildagliptin in bulk and pharmaceutical preparations

  2013cites this paper
• Diabetische Entgleisung im Alter

  2013cites this paper
• TWO Regulation of Glucose Homeostasis by GLP-1

  2013cites this paper
• P2–389: Saxagliptin: A dipeptidyl peptidase‐4 inhibitor ameliorates streptozotocin‐induced Alzheimer's disease

  2013cites this paper
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

  2013cites this paper
• Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

  2012cites this paper
• Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human

  2012cites this paper
• Characterization of the In Vitro and In Vivo Metabolism and Disposition and P450 Inhibition/Induction Profile of Saxagliptin in Human

  2012cites this paper
• The Role of Self-Monitoring of Blood Glucose in Glucagon-like Peptide-1-Based Treatment Approaches: A European Expert Recommendation

  2012cites this paper
• Simultaneous Estimation of Saxagliptin Hydrochloride and Metformin Hydrochloride in Active Pharmaceutical Ingrident by RP-HPLC

  2012cites this paper
• Glucagon-like Peptide 1 and Type 2 Diabetes: Targets and New Therapies

  2012influential citation
• Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers

  2012cites this paper
• A review of gliptins in 2011

  2012cites this paper
• Saxagliptin plus metformin combination therapy

  2012cites this paper
• [Incretin-based therapy for treating patients with type 2 diabetes].

  2011cites this paper
• The incretin axis in cardiovascular disease.

  2011cites this paper
• An HPLC Method for the Determination of Saxagliptin in Human Plasma with Fluorescence Detection

  2009cites this paper